Company Overview of Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products. The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products. Its Oral Technologies segment offers oral delivery technologies, including formulation, development, and manufacturing services for the oral dose forms comprising p...
14 Schoolhouse Road
Somerset, NJ 08873
Key Executives for Catalent Pharma Solutions, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Senior Vice President of Global Operations
Group President of Clinical Supply Services
President of Oral Technologies - Modified Release Technology
Compensation as of Fiscal Year 2015.
Catalent Pharma Solutions, Inc. Key Developments
Catalent Pharma Solutions GmbH Appoints Wetteny Joseph as President of Clinical Supply Services Unit
Oct 26 15
Catalent Pharma Solutions GmbH has appointed Wetteny Joseph as its new president of clinical supply services unit. Mr. Joseph first joined Catalent in 2008 as Corporate Controller, and in 2012, was charged with leading the finance function for the company's Modified Release Technologies business unit. In 2013, Mr. Joseph was promoted to vice president of Finance for Catalent's Development and Clinical Services division, which included the Clinical Supply Services business unit. Before joining Catalent, Mr. Joseph held senior financial positions at HD Supply, including CFO of a $1.2 billion business unit. He also served as Corporate Controller at Hughes Supply. In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries.
Catalent Pharma Appoints Julien Meissonnier as Vice President of Science and Technology
Oct 15 15
Catalent Pharma Solutions has appointed Julien Meissonnier as vice president of science and technology. Mr. Meissonnier had previously led Catalent's European softgel R&D team, focused on early stage screening activities.
3M and Catalent Obtain Outstanding Results in Purification and Clarification with 3M Emphaze AEX Hybrid Purifier
Aug 19 15
Catalent Pharma Solutions and 3M Purification Inc., recently investigated a novel purification approach that significantly increased the performance of the mAb purification process by enhancing the efficiency of the Protein A column. The process resulted in a substantially pharmaceutically pure product immediately after Protein A elution. The global monoclonal antibody (mAb) market exceeded USD 80 billion in 2013, and is predicted to top USD 100 billion in 2015. To sustain this rapid market growth into the future, the biopharmaceutical industry requires increasingly efficient mAb purification processes from discovery to commercial manufacturing.To meet this increasing product demand, product titers are increasing, pushing cell culture density and duration to increase. These cell culture characteristics lead to higher contaminant levels which, in turn, can affect the efficiency of Protein A chromatography. Protein A will continue to be the primary capture step of choice due to its specificity and ability to yield pure product. However, the increased contaminant load can cause the purity of the Protein A eluate to drop from 99.9% to the 98-99% range. While the exact causes and mechanisms of the decrease in Protein A column performance are still a very active topic of research, high concentrations of chromatin in cell culture fluid has been suggested to be a major agent that interferes with Protein A chromatography, and acts as a precipitation catalyst at various stages of the process. 3M Emphaze AEX Hybrid Purifier, the first single-use chromatography purification product line introduced by 3M, is designed to help biopharmaceutical manufacturers achieve high product purity early in the manufacturing process because this can markedly improve efficiency and process economics. The result is an all-synthetic clarifying product line containing both a novel anion exchange functional nonwoven-supported hydrogel and a fine particle, bioburden reduction membrane. The 3M Emphaze AEX Hybrid Purifier utilizes the high capacity Q-functional hydrogel and 0.2 µm polyamide membrane to provide a high degree of soluble and insoluble contaminants reduction. When used at the clarification stage, it is capable of providing greater than 4 log reduction of DNA in the cell culture fluid often with throughputs over 400 L/m2. To decrease the chromatin content of the cell culture fluid, Catalent incorporated a 3M Emphaze AEX Hybrid Purifier capsule in the place of a fine grade depth filter in the primary recovery process. In this process position, the results were outstanding, including greater than 4 logs reduction in DNA and an increase in the efficiency of the protein A eluate pool to nearly injectable product purity. Catalent perceives the consequences of this enhanced process performance to be far reaching. Depending on the specific process, it may enable: restructuring and simplification of the downstream polishing train and; elimination of the polishing train in the cases where product aggregate content is sufficiently low and final viral clearance is not required.
Similar Private Companies By Industry
Recent Private Companies Transactions